Kluwer Patent Blog

Fluticason, District Court The Hague (Rechtbank Den Haag), 26 January 2011

Peter Burgers (Brinkhof) · Tuesday, February 1st, 2011

The District Court of The Hague revoked Glaxo's European Patent and Supplementary Protection Certificate (SPC) for an inhalable combination of fluticasone and salmeterol due to lack of inventive step. This decision is put in a pan-European perspective, with reference to the UK case law on inventive step, as well as the parallel English, German and Irish proceedings. The District Court systematically discusses the various steps of the PSA (closest prior art, objective technical problem and could-would test) within the EPO framework, citing EPO case law and the EPO Guidelines. In addition, the Court also deals in general and in particular with 'bonus effects' and the requirements and existence of a prejudice.

A full summary of this case has been published on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



The Wolters Kluwer Future Ready Lawyer

Leading change



This entry was posted on Tuesday, February 1st, 2011 at 8:00 am and is filed under Case Law, Inventive step, Netherlands, Validity

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.